Regulatory and Washington

The Access to Increased Drug Disposal Act, which is backed by the National Association of Chain Drug Stores, was introduced by Sen. Joni Ernst, R-Ia., and co-sponsored by Sens. Chuck Grassley, R-Ia., and Richard Blumenthal, D-Conn.

The National Community Pharmacists Association’s new senior vice president of government affairs and director of its Advocacy Center Karry La Violette’s has been with the organization since 2011, during which time she has led federal government affairs program, which included Capitol Hill and Administration lobbying efforts.

The U.S. Food and Drug Administration has sent warning letters to companies illegally marketing pills and capsules labeled as dietary supplements that make unproven drug claims about protecting consumers from the dangers of sun exposure without meeting the FDA’s standards for safety and effectiveness.

The U.S. Food and Drug Administration is warning consumers that OTC teething products containing benzocaine pose a serious risk to infants and children and is asking that companies stop selling these products for such use.

The U.S. Food and Drug Administration announced on Tuesday that it has issued warning letters to three marketers and distributors of kratom products for illegally selling unapproved kratom-containing drug products with unproven claims about their ability to help in the treatment of opioid addiction and withdrawal.

A Massachusetts bill that would ban the sale of weight-loss and muscle-building dietary supplements to minors has been pulled and sent to a study by the Joint Committee on Public Health.

The U.S. Food and Drug Administration is requesting information, such as documents related to product marketing and research on product design, from four e-cigarette manufacturers as part of its effort to address the use of e-cigarettes among kids.

Pharmacy advocates and organizations are pushing for legislation that focuses on enabling pharmacies to deliver improved patient health, with two areas of the business coming to the fore — ensuring transparent reimbursements and fighting the opioid crisis.